nodes	percent_of_prediction	percent_of_DWPC	metapath
Salbutamol—CYP3A4—Topotecan—lung cancer	0.067	0.142	CbGbCtD
Salbutamol—CYP3A4—Gefitinib—lung cancer	0.0613	0.13	CbGbCtD
Salbutamol—CYP3A4—Teniposide—lung cancer	0.0594	0.126	CbGbCtD
Salbutamol—CYP3A4—Vinorelbine—lung cancer	0.0472	0.1	CbGbCtD
Salbutamol—CYP3A4—Crizotinib—lung cancer	0.0376	0.0796	CbGbCtD
Salbutamol—CYP3A4—Erlotinib—lung cancer	0.0362	0.0768	CbGbCtD
Salbutamol—CYP3A4—Paclitaxel—lung cancer	0.0332	0.0703	CbGbCtD
Salbutamol—CYP3A4—Irinotecan—lung cancer	0.0327	0.0694	CbGbCtD
Salbutamol—CYP3A4—Vinblastine—lung cancer	0.0291	0.0617	CbGbCtD
Salbutamol—CYP3A4—Etoposide—lung cancer	0.0262	0.0556	CbGbCtD
Salbutamol—CYP3A4—Docetaxel—lung cancer	0.024	0.0508	CbGbCtD
Salbutamol—CYP3A4—Doxorubicin—lung cancer	0.0179	0.0379	CbGbCtD
Salbutamol—Clenbuterol—CYP1A1—lung cancer	0.000875	0.488	CrCbGaD
Salbutamol—Nadolol—ABCB1—lung cancer	0.000482	0.269	CrCbGaD
Salbutamol—Isoprenaline—CYP1A1—lung cancer	0.000437	0.244	CrCbGaD
Salbutamol—Bronchitis—Doxorubicin—lung cancer	0.000231	0.000476	CcSEcCtD
Salbutamol—Dyspnoea—Paclitaxel—lung cancer	0.00023	0.000474	CcSEcCtD
Salbutamol—Somnolence—Paclitaxel—lung cancer	0.000229	0.000473	CcSEcCtD
Salbutamol—Decreased appetite—Etoposide—lung cancer	0.000229	0.000472	CcSEcCtD
Salbutamol—Chest pain—Docetaxel—lung cancer	0.000228	0.000471	CcSEcCtD
Salbutamol—Myalgia—Docetaxel—lung cancer	0.000228	0.000471	CcSEcCtD
Salbutamol—Arthralgia—Docetaxel—lung cancer	0.000228	0.000471	CcSEcCtD
Salbutamol—Nausea—Vinorelbine—lung cancer	0.000228	0.00047	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Etoposide—lung cancer	0.000227	0.000469	CcSEcCtD
Salbutamol—Dyspepsia—Paclitaxel—lung cancer	0.000227	0.000468	CcSEcCtD
Salbutamol—Body temperature increased—Cisplatin—lung cancer	0.000227	0.000468	CcSEcCtD
Salbutamol—Asthenia—Irinotecan—lung cancer	0.000227	0.000468	CcSEcCtD
Salbutamol—Fatigue—Etoposide—lung cancer	0.000227	0.000468	CcSEcCtD
Salbutamol—Pain—Etoposide—lung cancer	0.000225	0.000464	CcSEcCtD
Salbutamol—Constipation—Etoposide—lung cancer	0.000225	0.000464	CcSEcCtD
Salbutamol—Dysuria—Doxorubicin—lung cancer	0.000224	0.000463	CcSEcCtD
Salbutamol—Decreased appetite—Paclitaxel—lung cancer	0.000224	0.000463	CcSEcCtD
Salbutamol—Dry mouth—Docetaxel—lung cancer	0.000223	0.00046	CcSEcCtD
Salbutamol—Upper respiratory tract infection—Doxorubicin—lung cancer	0.000223	0.00046	CcSEcCtD
Salbutamol—Haemoglobin—Methotrexate—lung cancer	0.000223	0.00046	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000223	0.000459	CcSEcCtD
Salbutamol—Fatigue—Paclitaxel—lung cancer	0.000222	0.000459	CcSEcCtD
Salbutamol—Haemorrhage—Methotrexate—lung cancer	0.000222	0.000458	CcSEcCtD
Salbutamol—Asthenia—Gemcitabine—lung cancer	0.000221	0.000456	CcSEcCtD
Salbutamol—Constipation—Paclitaxel—lung cancer	0.000221	0.000455	CcSEcCtD
Salbutamol—Pain—Paclitaxel—lung cancer	0.000221	0.000455	CcSEcCtD
Salbutamol—Pharyngitis—Methotrexate—lung cancer	0.00022	0.000454	CcSEcCtD
Salbutamol—Urinary tract disorder—Methotrexate—lung cancer	0.000219	0.000452	CcSEcCtD
Salbutamol—Anaphylactic shock—Docetaxel—lung cancer	0.000219	0.000451	CcSEcCtD
Salbutamol—Oedema—Docetaxel—lung cancer	0.000219	0.000451	CcSEcCtD
Salbutamol—Pruritus—Gemcitabine—lung cancer	0.000218	0.00045	CcSEcCtD
Salbutamol—Urethral disorder—Methotrexate—lung cancer	0.000217	0.000449	CcSEcCtD
Salbutamol—Infection—Docetaxel—lung cancer	0.000217	0.000448	CcSEcCtD
Salbutamol—Feeling abnormal—Etoposide—lung cancer	0.000217	0.000447	CcSEcCtD
Salbutamol—Hyperglycaemia—Doxorubicin—lung cancer	0.000216	0.000447	CcSEcCtD
Salbutamol—Diarrhoea—Irinotecan—lung cancer	0.000216	0.000446	CcSEcCtD
Salbutamol—Gastrointestinal pain—Etoposide—lung cancer	0.000215	0.000444	CcSEcCtD
Salbutamol—Shock—Docetaxel—lung cancer	0.000215	0.000444	CcSEcCtD
Salbutamol—Nervous system disorder—Docetaxel—lung cancer	0.000214	0.000442	CcSEcCtD
Salbutamol—Drowsiness—Doxorubicin—lung cancer	0.000214	0.000441	CcSEcCtD
Salbutamol—Tachycardia—Docetaxel—lung cancer	0.000213	0.00044	CcSEcCtD
Salbutamol—Feeling abnormal—Paclitaxel—lung cancer	0.000213	0.000439	CcSEcCtD
Salbutamol—Skin disorder—Docetaxel—lung cancer	0.000212	0.000438	CcSEcCtD
Salbutamol—Hypersensitivity—Cisplatin—lung cancer	0.000212	0.000436	CcSEcCtD
Salbutamol—Gastrointestinal pain—Paclitaxel—lung cancer	0.000211	0.000435	CcSEcCtD
Salbutamol—Diarrhoea—Gemcitabine—lung cancer	0.000211	0.000435	CcSEcCtD
Salbutamol—Neuropathy peripheral—Doxorubicin—lung cancer	0.00021	0.000433	CcSEcCtD
Salbutamol—Dizziness—Irinotecan—lung cancer	0.000209	0.000431	CcSEcCtD
Salbutamol—Urticaria—Etoposide—lung cancer	0.000209	0.000431	CcSEcCtD
Salbutamol—Jaundice—Doxorubicin—lung cancer	0.000209	0.00043	CcSEcCtD
Salbutamol—Stomatitis—Doxorubicin—lung cancer	0.000209	0.00043	CcSEcCtD
Salbutamol—Anorexia—Docetaxel—lung cancer	0.000208	0.00043	CcSEcCtD
Salbutamol—Body temperature increased—Etoposide—lung cancer	0.000208	0.000429	CcSEcCtD
Salbutamol—Abdominal pain—Etoposide—lung cancer	0.000208	0.000429	CcSEcCtD
Salbutamol—Conjunctivitis—Doxorubicin—lung cancer	0.000208	0.000429	CcSEcCtD
Salbutamol—Urinary tract infection—Doxorubicin—lung cancer	0.000208	0.000429	CcSEcCtD
Salbutamol—Tinnitus—Methotrexate—lung cancer	0.000207	0.000427	CcSEcCtD
Salbutamol—Asthenia—Cisplatin—lung cancer	0.000206	0.000425	CcSEcCtD
Salbutamol—Cardiac disorder—Methotrexate—lung cancer	0.000206	0.000425	CcSEcCtD
Salbutamol—Sweating—Doxorubicin—lung cancer	0.000205	0.000423	CcSEcCtD
Salbutamol—Urticaria—Paclitaxel—lung cancer	0.000205	0.000423	CcSEcCtD
Salbutamol—Hypotension—Docetaxel—lung cancer	0.000204	0.000421	CcSEcCtD
Salbutamol—Haematuria—Doxorubicin—lung cancer	0.000204	0.000421	CcSEcCtD
Salbutamol—Abdominal pain—Paclitaxel—lung cancer	0.000204	0.000421	CcSEcCtD
Salbutamol—Body temperature increased—Paclitaxel—lung cancer	0.000204	0.000421	CcSEcCtD
Salbutamol—Epistaxis—Doxorubicin—lung cancer	0.000202	0.000416	CcSEcCtD
Salbutamol—Angiopathy—Methotrexate—lung cancer	0.000201	0.000415	CcSEcCtD
Salbutamol—Vomiting—Irinotecan—lung cancer	0.000201	0.000415	CcSEcCtD
Salbutamol—Sinusitis—Doxorubicin—lung cancer	0.000201	0.000414	CcSEcCtD
Salbutamol—Immune system disorder—Methotrexate—lung cancer	0.0002	0.000413	CcSEcCtD
Salbutamol—Mediastinal disorder—Methotrexate—lung cancer	0.0002	0.000412	CcSEcCtD
Salbutamol—Rash—Irinotecan—lung cancer	0.000199	0.000411	CcSEcCtD
Salbutamol—Dermatitis—Irinotecan—lung cancer	0.000199	0.000411	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000199	0.000411	CcSEcCtD
Salbutamol—Chills—Methotrexate—lung cancer	0.000199	0.000411	CcSEcCtD
Salbutamol—Headache—Irinotecan—lung cancer	0.000198	0.000409	CcSEcCtD
Salbutamol—Insomnia—Docetaxel—lung cancer	0.000198	0.000408	CcSEcCtD
Salbutamol—Diarrhoea—Cisplatin—lung cancer	0.000196	0.000405	CcSEcCtD
Salbutamol—Paraesthesia—Docetaxel—lung cancer	0.000196	0.000405	CcSEcCtD
Salbutamol—Vomiting—Gemcitabine—lung cancer	0.000196	0.000404	CcSEcCtD
Salbutamol—Dyspnoea—Docetaxel—lung cancer	0.000195	0.000402	CcSEcCtD
Salbutamol—Somnolence—Docetaxel—lung cancer	0.000194	0.000401	CcSEcCtD
Salbutamol—Mental disorder—Methotrexate—lung cancer	0.000194	0.000401	CcSEcCtD
Salbutamol—Rash—Gemcitabine—lung cancer	0.000194	0.000401	CcSEcCtD
Salbutamol—Dermatitis—Gemcitabine—lung cancer	0.000194	0.0004	CcSEcCtD
Salbutamol—Hypersensitivity—Etoposide—lung cancer	0.000194	0.0004	CcSEcCtD
Salbutamol—Malnutrition—Methotrexate—lung cancer	0.000193	0.000398	CcSEcCtD
Salbutamol—Haemoglobin—Doxorubicin—lung cancer	0.000193	0.000398	CcSEcCtD
Salbutamol—Headache—Gemcitabine—lung cancer	0.000193	0.000398	CcSEcCtD
Salbutamol—Rhinitis—Doxorubicin—lung cancer	0.000193	0.000397	CcSEcCtD
Salbutamol—Dyspepsia—Docetaxel—lung cancer	0.000192	0.000397	CcSEcCtD
Salbutamol—Haemorrhage—Doxorubicin—lung cancer	0.000192	0.000396	CcSEcCtD
Salbutamol—Hypoaesthesia—Doxorubicin—lung cancer	0.000191	0.000394	CcSEcCtD
Salbutamol—Pharyngitis—Doxorubicin—lung cancer	0.000191	0.000393	CcSEcCtD
Salbutamol—Decreased appetite—Docetaxel—lung cancer	0.00019	0.000392	CcSEcCtD
Salbutamol—Hypersensitivity—Paclitaxel—lung cancer	0.00019	0.000392	CcSEcCtD
Salbutamol—Urinary tract disorder—Doxorubicin—lung cancer	0.00019	0.000391	CcSEcCtD
Salbutamol—Dysgeusia—Methotrexate—lung cancer	0.000189	0.00039	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Docetaxel—lung cancer	0.000189	0.000389	CcSEcCtD
Salbutamol—Asthenia—Etoposide—lung cancer	0.000189	0.000389	CcSEcCtD
Salbutamol—Connective tissue disorder—Doxorubicin—lung cancer	0.000189	0.000389	CcSEcCtD
Salbutamol—Fatigue—Docetaxel—lung cancer	0.000189	0.000389	CcSEcCtD
Salbutamol—Urethral disorder—Doxorubicin—lung cancer	0.000188	0.000388	CcSEcCtD
Salbutamol—Nausea—Irinotecan—lung cancer	0.000188	0.000388	CcSEcCtD
Salbutamol—Pain—Docetaxel—lung cancer	0.000187	0.000386	CcSEcCtD
Salbutamol—Constipation—Docetaxel—lung cancer	0.000187	0.000386	CcSEcCtD
Salbutamol—Back pain—Methotrexate—lung cancer	0.000187	0.000385	CcSEcCtD
Salbutamol—Pruritus—Etoposide—lung cancer	0.000186	0.000384	CcSEcCtD
Salbutamol—Asthenia—Paclitaxel—lung cancer	0.000185	0.000382	CcSEcCtD
Salbutamol—Nausea—Gemcitabine—lung cancer	0.000183	0.000378	CcSEcCtD
Salbutamol—Vomiting—Cisplatin—lung cancer	0.000183	0.000377	CcSEcCtD
Salbutamol—Pruritus—Paclitaxel—lung cancer	0.000182	0.000376	CcSEcCtD
Salbutamol—Rash—Cisplatin—lung cancer	0.000181	0.000374	CcSEcCtD
Salbutamol—Dermatitis—Cisplatin—lung cancer	0.000181	0.000373	CcSEcCtD
Salbutamol—Feeling abnormal—Docetaxel—lung cancer	0.00018	0.000372	CcSEcCtD
Salbutamol—Diarrhoea—Etoposide—lung cancer	0.00018	0.000371	CcSEcCtD
Salbutamol—Ill-defined disorder—Methotrexate—lung cancer	0.000179	0.00037	CcSEcCtD
Salbutamol—Tinnitus—Doxorubicin—lung cancer	0.000179	0.000369	CcSEcCtD
Salbutamol—Gastrointestinal pain—Docetaxel—lung cancer	0.000179	0.000369	CcSEcCtD
Salbutamol—Cardiac disorder—Doxorubicin—lung cancer	0.000178	0.000368	CcSEcCtD
Salbutamol—Flushing—Doxorubicin—lung cancer	0.000178	0.000368	CcSEcCtD
Salbutamol—Diarrhoea—Paclitaxel—lung cancer	0.000176	0.000364	CcSEcCtD
Salbutamol—Angiopathy—Doxorubicin—lung cancer	0.000174	0.000359	CcSEcCtD
Salbutamol—Malaise—Methotrexate—lung cancer	0.000174	0.000359	CcSEcCtD
Salbutamol—Dizziness—Etoposide—lung cancer	0.000174	0.000359	CcSEcCtD
Salbutamol—Immune system disorder—Doxorubicin—lung cancer	0.000173	0.000358	CcSEcCtD
Salbutamol—Vertigo—Methotrexate—lung cancer	0.000173	0.000358	CcSEcCtD
Salbutamol—Mediastinal disorder—Doxorubicin—lung cancer	0.000173	0.000357	CcSEcCtD
Salbutamol—Abdominal pain—Docetaxel—lung cancer	0.000173	0.000357	CcSEcCtD
Salbutamol—Body temperature increased—Docetaxel—lung cancer	0.000173	0.000357	CcSEcCtD
Salbutamol—Chills—Doxorubicin—lung cancer	0.000172	0.000356	CcSEcCtD
Salbutamol—Arrhythmia—Doxorubicin—lung cancer	0.000172	0.000354	CcSEcCtD
Salbutamol—Dizziness—Paclitaxel—lung cancer	0.000171	0.000352	CcSEcCtD
Salbutamol—Nausea—Cisplatin—lung cancer	0.000171	0.000352	CcSEcCtD
Salbutamol—Cough—Methotrexate—lung cancer	0.000168	0.000348	CcSEcCtD
Salbutamol—Mental disorder—Doxorubicin—lung cancer	0.000168	0.000347	CcSEcCtD
Salbutamol—Vomiting—Etoposide—lung cancer	0.000167	0.000345	CcSEcCtD
Salbutamol—Malnutrition—Doxorubicin—lung cancer	0.000167	0.000345	CcSEcCtD
Salbutamol—Rash—Etoposide—lung cancer	0.000166	0.000342	CcSEcCtD
Salbutamol—Dermatitis—Etoposide—lung cancer	0.000166	0.000342	CcSEcCtD
Salbutamol—Headache—Etoposide—lung cancer	0.000165	0.00034	CcSEcCtD
Salbutamol—Flatulence—Doxorubicin—lung cancer	0.000165	0.00034	CcSEcCtD
Salbutamol—Arthralgia—Methotrexate—lung cancer	0.000164	0.000339	CcSEcCtD
Salbutamol—Chest pain—Methotrexate—lung cancer	0.000164	0.000339	CcSEcCtD
Salbutamol—Myalgia—Methotrexate—lung cancer	0.000164	0.000339	CcSEcCtD
Salbutamol—Tension—Doxorubicin—lung cancer	0.000164	0.000338	CcSEcCtD
Salbutamol—Vomiting—Paclitaxel—lung cancer	0.000164	0.000338	CcSEcCtD
Salbutamol—Dysgeusia—Doxorubicin—lung cancer	0.000164	0.000338	CcSEcCtD
Salbutamol—Rash—Paclitaxel—lung cancer	0.000163	0.000336	CcSEcCtD
Salbutamol—Dermatitis—Paclitaxel—lung cancer	0.000162	0.000335	CcSEcCtD
Salbutamol—Discomfort—Methotrexate—lung cancer	0.000162	0.000335	CcSEcCtD
Salbutamol—Nervousness—Doxorubicin—lung cancer	0.000162	0.000335	CcSEcCtD
Salbutamol—Back pain—Doxorubicin—lung cancer	0.000162	0.000334	CcSEcCtD
Salbutamol—Headache—Paclitaxel—lung cancer	0.000162	0.000333	CcSEcCtD
Salbutamol—Hypersensitivity—Docetaxel—lung cancer	0.000161	0.000332	CcSEcCtD
Salbutamol—Muscle spasms—Doxorubicin—lung cancer	0.000161	0.000332	CcSEcCtD
Salbutamol—Anaphylactic shock—Methotrexate—lung cancer	0.000158	0.000325	CcSEcCtD
Salbutamol—Asthenia—Docetaxel—lung cancer	0.000157	0.000324	CcSEcCtD
Salbutamol—Infection—Methotrexate—lung cancer	0.000157	0.000323	CcSEcCtD
Salbutamol—Nausea—Etoposide—lung cancer	0.000156	0.000322	CcSEcCtD
Salbutamol—Ill-defined disorder—Doxorubicin—lung cancer	0.000155	0.00032	CcSEcCtD
Salbutamol—Pruritus—Docetaxel—lung cancer	0.000155	0.000319	CcSEcCtD
Salbutamol—Nervous system disorder—Methotrexate—lung cancer	0.000155	0.000319	CcSEcCtD
Salbutamol—Agitation—Doxorubicin—lung cancer	0.000154	0.000317	CcSEcCtD
Salbutamol—Nausea—Paclitaxel—lung cancer	0.000153	0.000316	CcSEcCtD
Salbutamol—Skin disorder—Methotrexate—lung cancer	0.000153	0.000316	CcSEcCtD
Salbutamol—Hyperhidrosis—Methotrexate—lung cancer	0.000152	0.000314	CcSEcCtD
Salbutamol—Malaise—Doxorubicin—lung cancer	0.000151	0.000311	CcSEcCtD
Salbutamol—Vertigo—Doxorubicin—lung cancer	0.00015	0.00031	CcSEcCtD
Salbutamol—Anorexia—Methotrexate—lung cancer	0.00015	0.00031	CcSEcCtD
Salbutamol—Syncope—Doxorubicin—lung cancer	0.00015	0.000309	CcSEcCtD
Salbutamol—Diarrhoea—Docetaxel—lung cancer	0.00015	0.000309	CcSEcCtD
Salbutamol—Palpitations—Doxorubicin—lung cancer	0.000148	0.000305	CcSEcCtD
Salbutamol—Hypotension—Methotrexate—lung cancer	0.000147	0.000304	CcSEcCtD
Salbutamol—Loss of consciousness—Doxorubicin—lung cancer	0.000147	0.000303	CcSEcCtD
Salbutamol—Cough—Doxorubicin—lung cancer	0.000146	0.000301	CcSEcCtD
Salbutamol—Dizziness—Docetaxel—lung cancer	0.000145	0.000298	CcSEcCtD
Salbutamol—Hypertension—Doxorubicin—lung cancer	0.000144	0.000298	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000144	0.000296	CcSEcCtD
Salbutamol—Insomnia—Methotrexate—lung cancer	0.000143	0.000294	CcSEcCtD
Salbutamol—Myalgia—Doxorubicin—lung cancer	0.000142	0.000294	CcSEcCtD
Salbutamol—Arthralgia—Doxorubicin—lung cancer	0.000142	0.000294	CcSEcCtD
Salbutamol—Chest pain—Doxorubicin—lung cancer	0.000142	0.000294	CcSEcCtD
Salbutamol—Anxiety—Doxorubicin—lung cancer	0.000142	0.000293	CcSEcCtD
Salbutamol—Paraesthesia—Methotrexate—lung cancer	0.000142	0.000292	CcSEcCtD
Salbutamol—Discomfort—Doxorubicin—lung cancer	0.000141	0.00029	CcSEcCtD
Salbutamol—Dyspnoea—Methotrexate—lung cancer	0.00014	0.00029	CcSEcCtD
Salbutamol—Somnolence—Methotrexate—lung cancer	0.00014	0.000289	CcSEcCtD
Salbutamol—Dry mouth—Doxorubicin—lung cancer	0.000139	0.000287	CcSEcCtD
Salbutamol—Vomiting—Docetaxel—lung cancer	0.000139	0.000287	CcSEcCtD
Salbutamol—Dyspepsia—Methotrexate—lung cancer	0.000139	0.000286	CcSEcCtD
Salbutamol—Rash—Docetaxel—lung cancer	0.000138	0.000284	CcSEcCtD
Salbutamol—Dermatitis—Docetaxel—lung cancer	0.000138	0.000284	CcSEcCtD
Salbutamol—Decreased appetite—Methotrexate—lung cancer	0.000137	0.000283	CcSEcCtD
Salbutamol—Headache—Docetaxel—lung cancer	0.000137	0.000283	CcSEcCtD
Salbutamol—Anaphylactic shock—Doxorubicin—lung cancer	0.000136	0.000282	CcSEcCtD
Salbutamol—Oedema—Doxorubicin—lung cancer	0.000136	0.000282	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Methotrexate—lung cancer	0.000136	0.000281	CcSEcCtD
Salbutamol—Fatigue—Methotrexate—lung cancer	0.000136	0.00028	CcSEcCtD
Salbutamol—Infection—Doxorubicin—lung cancer	0.000136	0.00028	CcSEcCtD
Salbutamol—Pain—Methotrexate—lung cancer	0.000135	0.000278	CcSEcCtD
Salbutamol—Shock—Doxorubicin—lung cancer	0.000134	0.000277	CcSEcCtD
Salbutamol—Nervous system disorder—Doxorubicin—lung cancer	0.000134	0.000276	CcSEcCtD
Salbutamol—Tachycardia—Doxorubicin—lung cancer	0.000133	0.000275	CcSEcCtD
Salbutamol—Skin disorder—Doxorubicin—lung cancer	0.000133	0.000273	CcSEcCtD
Salbutamol—Hyperhidrosis—Doxorubicin—lung cancer	0.000132	0.000272	CcSEcCtD
Salbutamol—Anorexia—Doxorubicin—lung cancer	0.00013	0.000268	CcSEcCtD
Salbutamol—Nausea—Docetaxel—lung cancer	0.00013	0.000268	CcSEcCtD
Salbutamol—Feeling abnormal—Methotrexate—lung cancer	0.00013	0.000268	CcSEcCtD
Salbutamol—Gastrointestinal pain—Methotrexate—lung cancer	0.000129	0.000266	CcSEcCtD
Salbutamol—Hypotension—Doxorubicin—lung cancer	0.000128	0.000263	CcSEcCtD
Salbutamol—Urticaria—Methotrexate—lung cancer	0.000125	0.000258	CcSEcCtD
Salbutamol—Abdominal pain—Methotrexate—lung cancer	0.000125	0.000257	CcSEcCtD
Salbutamol—Body temperature increased—Methotrexate—lung cancer	0.000125	0.000257	CcSEcCtD
Salbutamol—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000124	0.000256	CcSEcCtD
Salbutamol—Insomnia—Doxorubicin—lung cancer	0.000123	0.000255	CcSEcCtD
Salbutamol—Paraesthesia—Doxorubicin—lung cancer	0.000123	0.000253	CcSEcCtD
Salbutamol—Dyspnoea—Doxorubicin—lung cancer	0.000122	0.000251	CcSEcCtD
Salbutamol—Somnolence—Doxorubicin—lung cancer	0.000121	0.00025	CcSEcCtD
Salbutamol—Dyspepsia—Doxorubicin—lung cancer	0.00012	0.000248	CcSEcCtD
Salbutamol—Decreased appetite—Doxorubicin—lung cancer	0.000119	0.000245	CcSEcCtD
Salbutamol—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000118	0.000243	CcSEcCtD
Salbutamol—Fatigue—Doxorubicin—lung cancer	0.000118	0.000243	CcSEcCtD
Salbutamol—Pain—Doxorubicin—lung cancer	0.000117	0.000241	CcSEcCtD
Salbutamol—Constipation—Doxorubicin—lung cancer	0.000117	0.000241	CcSEcCtD
Salbutamol—Hypersensitivity—Methotrexate—lung cancer	0.000116	0.00024	CcSEcCtD
Salbutamol—Asthenia—Methotrexate—lung cancer	0.000113	0.000233	CcSEcCtD
Salbutamol—Feeling abnormal—Doxorubicin—lung cancer	0.000112	0.000232	CcSEcCtD
Salbutamol—Gastrointestinal pain—Doxorubicin—lung cancer	0.000112	0.00023	CcSEcCtD
Salbutamol—Pruritus—Methotrexate—lung cancer	0.000111	0.00023	CcSEcCtD
Salbutamol—Urticaria—Doxorubicin—lung cancer	0.000108	0.000224	CcSEcCtD
Salbutamol—Body temperature increased—Doxorubicin—lung cancer	0.000108	0.000223	CcSEcCtD
Salbutamol—Abdominal pain—Doxorubicin—lung cancer	0.000108	0.000223	CcSEcCtD
Salbutamol—Diarrhoea—Methotrexate—lung cancer	0.000108	0.000222	CcSEcCtD
Salbutamol—Dizziness—Methotrexate—lung cancer	0.000104	0.000215	CcSEcCtD
Salbutamol—Hypersensitivity—Doxorubicin—lung cancer	0.000101	0.000207	CcSEcCtD
Salbutamol—Vomiting—Methotrexate—lung cancer	0.0001	0.000207	CcSEcCtD
Salbutamol—Rash—Methotrexate—lung cancer	9.94e-05	0.000205	CcSEcCtD
Salbutamol—Dermatitis—Methotrexate—lung cancer	9.93e-05	0.000205	CcSEcCtD
Salbutamol—Headache—Methotrexate—lung cancer	9.87e-05	0.000204	CcSEcCtD
Salbutamol—Asthenia—Doxorubicin—lung cancer	9.79e-05	0.000202	CcSEcCtD
Salbutamol—Pruritus—Doxorubicin—lung cancer	9.65e-05	0.000199	CcSEcCtD
Salbutamol—Nausea—Methotrexate—lung cancer	9.36e-05	0.000193	CcSEcCtD
Salbutamol—Diarrhoea—Doxorubicin—lung cancer	9.34e-05	0.000193	CcSEcCtD
Salbutamol—Dizziness—Doxorubicin—lung cancer	9.02e-05	0.000186	CcSEcCtD
Salbutamol—Vomiting—Doxorubicin—lung cancer	8.68e-05	0.000179	CcSEcCtD
Salbutamol—Rash—Doxorubicin—lung cancer	8.6e-05	0.000177	CcSEcCtD
Salbutamol—Dermatitis—Doxorubicin—lung cancer	8.6e-05	0.000177	CcSEcCtD
Salbutamol—Headache—Doxorubicin—lung cancer	8.55e-05	0.000176	CcSEcCtD
Salbutamol—Nausea—Doxorubicin—lung cancer	8.11e-05	0.000167	CcSEcCtD
Salbutamol—ADRB1—Signaling Pathways—SKI—lung cancer	4.41e-05	0.00106	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—POMC—lung cancer	4.36e-05	0.00105	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—APP—lung cancer	4.33e-05	0.00104	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SKI—lung cancer	4.32e-05	0.00104	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—GSTM1—lung cancer	4.28e-05	0.00103	CbGpPWpGaD
Salbutamol—CYP3A4—Metapathway biotransformation—GSTM1—lung cancer	4.23e-05	0.00101	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—CYP1A1—lung cancer	4.06e-05	0.000975	CbGpPWpGaD
Salbutamol—CYP3A4—Metapathway biotransformation—CYP1A1—lung cancer	4.01e-05	0.000962	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PXN—lung cancer	3.83e-05	0.00092	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—AVP—lung cancer	3.79e-05	0.000911	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—AKR1C1—lung cancer	3.75e-05	0.000901	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GRP—lung cancer	3.75e-05	0.000901	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—OXTR—lung cancer	3.75e-05	0.000901	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PXN—lung cancer	3.75e-05	0.0009	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—AVP—lung cancer	3.71e-05	0.000891	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GRP—lung cancer	3.67e-05	0.000881	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—AKR1C1—lung cancer	3.67e-05	0.000881	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—OXTR—lung cancer	3.67e-05	0.000881	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—AZIN2—lung cancer	3.57e-05	0.000858	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—COL4A3BP—lung cancer	3.57e-05	0.000858	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—GNG11—lung cancer	3.51e-05	0.000843	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—CXCL8—lung cancer	3.45e-05	0.000828	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—AVP—lung cancer	3.44e-05	0.000827	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—GNG11—lung cancer	3.44e-05	0.000825	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—CXCL8—lung cancer	3.38e-05	0.00081	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—AVP—lung cancer	3.37e-05	0.000809	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—VEGFC—lung cancer	3.34e-05	0.000803	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—VEGFC—lung cancer	3.27e-05	0.000785	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ADCY1—lung cancer	3.16e-05	0.000758	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ADCY1—lung cancer	3.09e-05	0.000742	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PPP2R1B—lung cancer	3.08e-05	0.000739	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SMARCA4—lung cancer	3.08e-05	0.000739	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ATP5H—lung cancer	3.04e-05	0.000729	CbGpPWpGaD
Salbutamol—CYP3A4—Biological oxidations—POMC—lung cancer	3.03e-05	0.000727	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PPP2R1B—lung cancer	3.01e-05	0.000723	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SMARCA4—lung cancer	3.01e-05	0.000723	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HSPB1—lung cancer	2.97e-05	0.000713	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PTHLH—lung cancer	2.94e-05	0.000705	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HSPB1—lung cancer	2.9e-05	0.000697	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PTHLH—lung cancer	2.87e-05	0.000689	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ANXA1—lung cancer	2.76e-05	0.000663	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PLBD1—lung cancer	2.71e-05	0.00065	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ANXA1—lung cancer	2.7e-05	0.000648	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FLT1—lung cancer	2.67e-05	0.000642	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PIK3CG—lung cancer	2.65e-05	0.000636	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—APP—lung cancer	2.62e-05	0.000628	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NOTCH3—lung cancer	2.62e-05	0.000628	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FLT1—lung cancer	2.61e-05	0.000628	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FGF9—lung cancer	2.59e-05	0.000623	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PIK3CG—lung cancer	2.59e-05	0.000622	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NOTCH3—lung cancer	2.56e-05	0.000614	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—APP—lung cancer	2.56e-05	0.000614	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FGF9—lung cancer	2.54e-05	0.000609	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—POMC—lung cancer	2.52e-05	0.000605	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—JUNB—lung cancer	2.48e-05	0.000595	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HSD17B10—lung cancer	2.48e-05	0.000595	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—POMC—lung cancer	2.47e-05	0.000592	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—JUNB—lung cancer	2.42e-05	0.000582	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PIK3CG—lung cancer	2.4e-05	0.000577	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PIK3CG—lung cancer	2.35e-05	0.000565	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PIK3CD—lung cancer	2.33e-05	0.000559	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CKB—lung cancer	2.3e-05	0.000553	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—POMC—lung cancer	2.29e-05	0.00055	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PIK3CD—lung cancer	2.28e-05	0.000547	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—STK11—lung cancer	2.25e-05	0.00054	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—POMC—lung cancer	2.24e-05	0.000538	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—IL6R—lung cancer	2.23e-05	0.000536	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—STK11—lung cancer	2.2e-05	0.000528	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—IL6R—lung cancer	2.18e-05	0.000524	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FOXO3—lung cancer	2.17e-05	0.000521	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTM2—lung cancer	2.16e-05	0.00052	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CNDP2—lung cancer	2.16e-05	0.00052	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—MAP2K1—lung cancer	2.13e-05	0.000511	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FOXO3—lung cancer	2.12e-05	0.00051	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PIK3CD—lung cancer	2.11e-05	0.000507	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—MTMR3—lung cancer	2.11e-05	0.000506	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—MAP2K1—lung cancer	2.08e-05	0.0005	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PIK3CD—lung cancer	2.07e-05	0.000496	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PGAM1—lung cancer	2.05e-05	0.000493	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—AVP—lung cancer	2.03e-05	0.000488	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PIK3CB—lung cancer	2.03e-05	0.000487	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—AVP—lung cancer	1.99e-05	0.000478	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PIK3CB—lung cancer	1.98e-05	0.000477	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IGF1R—lung cancer	1.96e-05	0.00047	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP2A7—lung cancer	1.96e-05	0.00047	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—CXCL8—lung cancer	1.95e-05	0.000468	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HES1—lung cancer	1.92e-05	0.000462	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IGF1R—lung cancer	1.92e-05	0.00046	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—SDC4—lung cancer	1.92e-05	0.00046	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—CXCL8—lung cancer	1.91e-05	0.000458	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—RAF1—lung cancer	1.89e-05	0.000453	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HES1—lung cancer	1.88e-05	0.000452	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—IL2—lung cancer	1.86e-05	0.000447	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—RAF1—lung cancer	1.85e-05	0.000443	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PIK3CB—lung cancer	1.84e-05	0.000442	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—IL2—lung cancer	1.82e-05	0.000438	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PIK3CB—lung cancer	1.8e-05	0.000433	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—CXCL8—lung cancer	1.77e-05	0.000425	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ERBB3—lung cancer	1.76e-05	0.000422	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTA3—lung cancer	1.74e-05	0.000419	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—RRM1—lung cancer	1.74e-05	0.000419	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—CXCL8—lung cancer	1.73e-05	0.000416	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ERBB3—lung cancer	1.72e-05	0.000413	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—IL2—lung cancer	1.69e-05	0.000406	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TERT—lung cancer	1.69e-05	0.000405	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—IL2—lung cancer	1.66e-05	0.000397	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TERT—lung cancer	1.65e-05	0.000396	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—B4GALT5—lung cancer	1.64e-05	0.000394	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—FGFR1—lung cancer	1.64e-05	0.000393	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HIF1A—lung cancer	1.61e-05	0.000387	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—FGFR1—lung cancer	1.6e-05	0.000384	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTA4—lung cancer	1.6e-05	0.000383	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HIF1A—lung cancer	1.58e-05	0.000379	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—APOA1—lung cancer	1.56e-05	0.000374	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTA2—lung cancer	1.56e-05	0.000373	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—KDR—lung cancer	1.54e-05	0.00037	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—APOA1—lung cancer	1.52e-05	0.000365	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—KDR—lung cancer	1.51e-05	0.000362	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTA1—lung cancer	1.5e-05	0.00036	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ABCC3—lung cancer	1.48e-05	0.000356	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—AKR1C1—lung cancer	1.44e-05	0.000345	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—KIT—lung cancer	1.42e-05	0.000341	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PIK3CG—lung cancer	1.42e-05	0.000341	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—APC—lung cancer	1.42e-05	0.000341	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—NRAS—lung cancer	1.42e-05	0.000341	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—EGF—lung cancer	1.4e-05	0.000337	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—UGT1A1—lung cancer	1.39e-05	0.000335	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—APC—lung cancer	1.39e-05	0.000334	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PIK3CG—lung cancer	1.39e-05	0.000334	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—KIT—lung cancer	1.39e-05	0.000334	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—NRAS—lung cancer	1.39e-05	0.000334	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—EGF—lung cancer	1.37e-05	0.00033	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—MAPK3—lung cancer	1.36e-05	0.000327	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—POMC—lung cancer	1.35e-05	0.000325	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GNG11—lung cancer	1.35e-05	0.000323	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—BRAF—lung cancer	1.34e-05	0.000321	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—MAPK3—lung cancer	1.33e-05	0.000319	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—POMC—lung cancer	1.32e-05	0.000318	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IL6R—lung cancer	1.32e-05	0.000317	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CREBBP—lung cancer	1.32e-05	0.000316	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—BRAF—lung cancer	1.31e-05	0.000314	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—EGFR—lung cancer	1.29e-05	0.000311	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IL6R—lung cancer	1.29e-05	0.00031	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CREBBP—lung cancer	1.29e-05	0.000309	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ALDOA—lung cancer	1.28e-05	0.000307	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—EGFR—lung cancer	1.27e-05	0.000304	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MAP2K1—lung cancer	1.26e-05	0.000302	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PIK3CD—lung cancer	1.25e-05	0.0003	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NCOA3—lung cancer	1.24e-05	0.000298	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—PIK3CA—lung cancer	1.24e-05	0.000297	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MAP2K1—lung cancer	1.23e-05	0.000295	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—KRAS—lung cancer	1.22e-05	0.000294	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PIK3CD—lung cancer	1.22e-05	0.000293	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—PIK3CA—lung cancer	1.21e-05	0.00029	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ADCY1—lung cancer	1.21e-05	0.00029	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ABCG2—lung cancer	1.21e-05	0.00029	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—KRAS—lung cancer	1.2e-05	0.000287	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ENO2—lung cancer	1.19e-05	0.000285	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HPGDS—lung cancer	1.19e-05	0.000285	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PPP2R1B—lung cancer	1.18e-05	0.000283	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTT1—lung cancer	1.15e-05	0.000276	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GCLC—lung cancer	1.14e-05	0.000273	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP2A6—lung cancer	1.14e-05	0.000273	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—PIK3CA—lung cancer	1.12e-05	0.00027	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MDM2—lung cancer	1.12e-05	0.000269	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—RAF1—lung cancer	1.11e-05	0.000268	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—ERBB2—lung cancer	1.1e-05	0.000265	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—PIK3CA—lung cancer	1.1e-05	0.000264	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MDM2—lung cancer	1.09e-05	0.000263	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—RAF1—lung cancer	1.09e-05	0.000262	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MTOR—lung cancer	1.09e-05	0.000261	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PIK3CB—lung cancer	1.09e-05	0.000261	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—ERBB2—lung cancer	1.08e-05	0.000259	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ENO1—lung cancer	1.08e-05	0.000259	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MTOR—lung cancer	1.06e-05	0.000256	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PIK3CB—lung cancer	1.06e-05	0.000256	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CXCL8—lung cancer	1.05e-05	0.000251	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—HRAS—lung cancer	1.04e-05	0.000249	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CXCL8—lung cancer	1.02e-05	0.000246	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—HRAS—lung cancer	1.02e-05	0.000244	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—AKT1—lung cancer	1.01e-05	0.000243	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CASP3—lung cancer	1e-05	0.00024	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IL2—lung cancer	1e-05	0.00024	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—IL6—lung cancer	9.95e-06	0.000239	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—AKT1—lung cancer	9.88e-06	0.000237	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CASP3—lung cancer	9.79e-06	0.000235	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IL2—lung cancer	9.78e-06	0.000235	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CCND1—lung cancer	9.74e-06	0.000234	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—IL6—lung cancer	9.73e-06	0.000234	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—JUN—lung cancer	9.72e-06	0.000233	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP2E1—lung cancer	9.67e-06	0.000232	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—NQO1—lung cancer	9.56e-06	0.00023	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CCND1—lung cancer	9.53e-06	0.000229	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—JUN—lung cancer	9.51e-06	0.000228	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MMP9—lung cancer	9.46e-06	0.000227	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—CDKN1A—lung cancer	9.43e-06	0.000226	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PTEN—lung cancer	9.41e-06	0.000226	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MMP9—lung cancer	9.25e-06	0.000222	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—CDKN1A—lung cancer	9.22e-06	0.000221	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PTEN—lung cancer	9.2e-06	0.000221	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—AKT1—lung cancer	9.18e-06	0.00022	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—AKT1—lung cancer	8.98e-06	0.000215	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—EP300—lung cancer	8.97e-06	0.000215	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—EP300—lung cancer	8.77e-06	0.000211	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—SRC—lung cancer	8.72e-06	0.000209	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—STK11—lung cancer	8.62e-06	0.000207	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—SRC—lung cancer	8.53e-06	0.000205	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—VEGFA—lung cancer	8.5e-06	0.000204	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—STAT3—lung cancer	8.41e-06	0.000202	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—NRAS—lung cancer	8.39e-06	0.000201	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—VEGFA—lung cancer	8.31e-06	0.0002	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—STAT3—lung cancer	8.23e-06	0.000198	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—NRAS—lung cancer	8.21e-06	0.000197	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MAPK3—lung cancer	8.04e-06	0.000193	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTP1—lung cancer	7.97e-06	0.000191	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MAPK3—lung cancer	7.86e-06	0.000189	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—MYC—lung cancer	7.82e-06	0.000188	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CAT—lung cancer	7.76e-06	0.000186	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—MYC—lung cancer	7.65e-06	0.000184	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—EGFR—lung cancer	7.65e-06	0.000184	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ABCB1—lung cancer	7.55e-06	0.000181	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—EGFR—lung cancer	7.48e-06	0.00018	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—TYMS—lung cancer	7.41e-06	0.000178	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—GSTM1—lung cancer	7.33e-06	0.000176	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—KRAS—lung cancer	7.22e-06	0.000173	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—KRAS—lung cancer	7.07e-06	0.00017	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CYP1A1—lung cancer	6.95e-06	0.000167	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ERCC2—lung cancer	6.89e-06	0.000165	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—PIK3CA—lung cancer	6.64e-06	0.000159	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—PIK3CA—lung cancer	6.49e-06	0.000156	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—TP53—lung cancer	6.42e-06	0.000154	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—TP53—lung cancer	6.28e-06	0.000151	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HRAS—lung cancer	6.14e-06	0.000147	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HRAS—lung cancer	6.01e-06	0.000144	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—APOA1—lung cancer	5.96e-06	0.000143	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—IL6—lung cancer	5.88e-06	0.000141	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—IL6—lung cancer	5.75e-06	0.000138	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PIK3CG—lung cancer	5.44e-06	0.000131	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—AKT1—lung cancer	5.42e-06	0.00013	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—AKT1—lung cancer	5.3e-06	0.000127	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—POMC—lung cancer	5.18e-06	0.000124	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—CREBBP—lung cancer	5.04e-06	0.000121	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PIK3CD—lung cancer	4.78e-06	0.000115	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—ALB—lung cancer	4.72e-06	0.000113	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PIK3CB—lung cancer	4.17e-06	0.0001	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PTGS2—lung cancer	4.13e-06	9.92e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PTEN—lung cancer	3.6e-06	8.65e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—EP300—lung cancer	3.44e-06	8.25e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—PIK3CA—lung cancer	2.54e-06	6.1e-05	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—AKT1—lung cancer	2.08e-06	4.98e-05	CbGpPWpGaD
